Efficacy and safety of nab-paclitaxel plus gemcitabine (AG) vs. FOLFIRINOX (FFX) as first line chemotherapy for metastatic pancreatic cancer (mPC): Retrospective analysis
被引:0
作者:
Lee, K.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Ulsan, Coll Med, Asan Med Ctr, Oncol, Seoul, South KoreaUniv Ulsan, Coll Med, Asan Med Ctr, Oncol, Seoul, South Korea
Lee, K.
[1
]
论文数: 引用数:
h-index:
机构:
Hwang, I.
[1
]
Kang, J.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Ulsan, Coll Med, Asan Med Ctr, Oncol, Seoul, South KoreaUniv Ulsan, Coll Med, Asan Med Ctr, Oncol, Seoul, South Korea
Kang, J.
[1
]
Yoo, C.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Ulsan, Coll Med, Asan Med Ctr, Oncol, Seoul, South KoreaUniv Ulsan, Coll Med, Asan Med Ctr, Oncol, Seoul, South Korea
Yoo, C.
[1
]
Kim, K-P.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Ulsan, Coll Med, Asan Med Ctr, Oncol, Seoul, South KoreaUniv Ulsan, Coll Med, Asan Med Ctr, Oncol, Seoul, South Korea
Kim, K-P.
[1
]
论文数: 引用数:
h-index:
机构:
Jeong, J. H.
[1
]
Chang, H-M.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Ulsan, Coll Med, Asan Med Ctr, Oncol, Seoul, South KoreaUniv Ulsan, Coll Med, Asan Med Ctr, Oncol, Seoul, South Korea
Chang, H-M.
[1
]
Ryoo, B-Y.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Ulsan, Coll Med, Asan Med Ctr, Oncol, Seoul, South KoreaUniv Ulsan, Coll Med, Asan Med Ctr, Oncol, Seoul, South Korea
Ryoo, B-Y.
[1
]
机构:
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Oncol, Seoul, South Korea